JAN 27, 2021 8:30 AM PST

Do Vaccines Work Against New Covid Variants?

WRITTEN BY: Annie Lennon

The SARS-CoV-2 virus is mutating faster than scientists previously thought. As such, pharmaceutical companies are now scrambling to both test whether their vaccines are effective against new variants of the virus and to develop booster shots. 

Currently, both Moderna and Pfizer-BioNTech have said that their vaccines appear to be effective against the new variants of coronavirus in the UK and South Africa, although they are both less protective against the South African variant. As such, protection against this variant may disappear more quickly unless further measures are taken. 

To this end, Moderna has started to develop a new form of its vaccine to be used as a booster shot against the South African variant. While Moderna's chief medical officer, Dr. Tal Zaks, says that they hope it will not be necessary, they are developing it as 'an insurance policy'. The company has also said that it plans to begin testing whether giving patients a third shot of its original vaccine may help fend off new variants. 

Moreover, in a recent experiment that is yet to be published or peer-reviewed, Moderna examined blood samples from eight people, and two monkeys had received two doses of their vaccine. While they found that the vaccine was similarly effective against both the original and British variant of the virus, antibodies produced by the vaccine appeared to be six times less effective against the South African variant. Nevertheless, the company said that their antibodies remained above minimum protective levels. 

Meanwhile, BioNTech is now in discussions with regulators to define the types of clinical trials needed worldwide to authorize a new version of the Pfizer-BioNTech vaccine that would be better able to fend off the South African variant. Although the company says it could develop a new vaccine capable of tackling new variants in just six weeks, the Food and Drug Administration is yet to comment on policy for authorizing such 'updated' vaccines. 

 

Sources: bioRxivBBCThe New York Times

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUN 29, 2021
Microbiology
Gut Fungi May Be an Untapped Reservoir of Antibiotics
JUN 29, 2021
Gut Fungi May Be an Untapped Reservoir of Antibiotics
Viruses are not the only microbes that can cause serious public health problems. Researchers have been warning about a p ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
AUG 05, 2021
Cannabis Sciences
Brain's Version of THC Reduces Seizures, Increases Side Effects
AUG 05, 2021
Brain's Version of THC Reduces Seizures, Increases Side Effects
An endocannabinoid similar to tetrahydrocannabinol (THC) that naturally occurs in the brain reduces seizure activity. Ho ...
AUG 10, 2021
Immunology
A Tapeworm Drug as a COVID Antiviral?
AUG 10, 2021
A Tapeworm Drug as a COVID Antiviral?
A study by researchers at the Scripps Research Institute looking into potential COVID-19 medications has revealed a surp ...
AUG 24, 2021
Drug Discovery & Development
A comparison of drugs for relapsing-remitting multiple sclerosis.
AUG 24, 2021
A comparison of drugs for relapsing-remitting multiple sclerosis.
     Multiple sclerosis (MS) is a rare and unpredictable autoimmune disease in which the body’s inn ...
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
Loading Comments...